Quark Aims for Five Clinical Indications, New IND in 2010 (GenomeWeb News)
November 30th, 2009
With the completion of enrollment in a phase II study of its siRNA-based treatment for diabetic macular edema, which was exclusively licensed to Pfizer, Quark Pharmaceuticals said earlier this month that it is on track to have three drugs in the clinic for five indications next year.
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)